Investor Presentaiton
ersonal use only
Cashflow
US$'000
FY19
FY20
Net loss
(13,294)
(12,446)
Convertible note related expenses
Other non-cash adjustments
6,684
548
1,548
•
Change in other assets and liabilities
(566)
(1,333)
Operating cash flows
(6,628)
(12,231)
Investing cash flows
(529)
Proceeds from issuance of common stock (net)
7,222
(774)
33,407
Proceeds from convertible notes
Proceeds from financing obligation
Other financing activities
Financing cash flows
1,746 1
1,700
(217)
(382)
10,451
33,025
Net change in cash
3,294
20,020
Effect of foreign currency changes on cash
Cash at 31 December
166
71
5,049
25,140
27
27
Commentary
•
•
Other non-cash adjustments are primarily related to deprecation
and stock-related compensation expense
Net operating cash outflows increased $5.6 million on the prior
comparative period due primarily to additional staffing, D&O
insurance, public company costs and building inventory
Investing cash outflows consisted of purchases of manufacturing
and R&D equipment and payments for security deposits. During
2020, investing cash outflows also includes leasehold
improvements and furniture related to the build out of additional
R&D space
2019 Proceeds from issuance of common stock includes $7.0
million related to the Company's IPO and $0.2 related to the
exercise of options and warrants
2019 Proceeds from financing obligation relates to the sale-
leaseback of the Company's MRI scanner
2020 Proceeds from issuance of common stock includes $12.6
million related to the Company's February placement, $19.2
million related to the Company's November placement, $1.1
million related to the Company's December Security Purchase Plan
and $0.5 related to the exercise of options and warrants
Imricor FY20 Investor Presentation, February 2021View entire presentation